Johnson & Johnson (JNJ) 10-K Summary — Year Ended Dec 29, 2024
Johnson & Johnson is a healthcare company with two segments: Innovative Medicine and MedTech. The company reported increased revenue, net income, and strong operating cash flow for the fiscal year.
Key takeaway
Year ended Dec 29, 2024 · FY2025 10-K
Johnson & Johnson is a healthcare company with two segments: Innovative Medicine and MedTech. The company reported increased revenue, net income, and strong operating cash flow for the fiscal year.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$88.8B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$14.1B
Net income reported for the year.
Operating cash flow
$24.3B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jul 2, 2023 | $21.5B | n/a |
| Oct 1, 2023 | $21.4B | -0.8% |
| Dec 31, 2023 | $85.2B | +298.9% |
| Dec 29, 2024 | $88.8B | +4.3% |
Business overview
The company operates through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). It focuses on products related to human health and well-being, with operations worldwide. The Chief Executive Officer and Executive Committee set strategy, while operating companies manage day-to-day activities.
Financial performance
Revenue increased compared to the prior year. Net income was reported, and cash generated from operations was substantial. The company's financial direction reflects growth in top-line sales and healthy cash generation.
Material risks
The filing discusses legal proceedings as a risk factor and includes a cautionary note regarding forward-looking statements, which involve uncertainties. The company operates in a highly regulated industry and faces potential litigation and market risks.
Liquidity and capital
Cash and cash equivalents increased from the prior year end, primarily driven by operating cash flows. Investing and financing activities used cash, including additions to property, plant, and equipment.
What to watch
Readers should monitor developments in legal proceedings, as they are highlighted as a risk factor in the filing.